학술논문
373O - Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)
Document Type
Abstract
Author
Source
In Annals of Oncology October 2018 29 Supplement 8
Subject
Language
ISSN
0923-7534